-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 20, Microchip released an announcement that the Phase 2 trial of chidamide combined with envolimab in the treatment of non-small cell lung cancer (NSCLC) patients who have been treated with PD-1 inhibitors has been received from China.
New Drug Clinical Trial Application (IND) Acceptance Notice issued by the Drug Administration (NMPA).
This is another recent progress made by the Microchip Technology Innovation Product Pipeline after Sioroni was successively approved for clinical trials in China and the United States.
Chidamide: Combined with anti-PD-L1 antibody Phase 2 clinical acceptance, Chidamide, independently developed by Chipchip Biosciences, is the world's first subtype-selective histone deacetylase (HDAC) oral inhibitor, which is already in China Approved for the treatment of peripheral T-cell lymphoma and breast cancer indications, and is currently conducting pivotal phase 3 clinical trials in the indications of diffuse large B-cell lymphoma (DLBCL).
According to the announcement, the NMPA accepted this time is an open, multi-center phase 2 clinical study of chidamide combined with envolimab in the treatment of NSCLC patients who have been treated with PD-1 inhibitors.
Sioroni: successively approved for clinical trials in China and the United States
Chiauranib (CS2164) is a multi-target multi-pathway selective kinase inhibitor that can exert comprehensive anti-tumor effects through three active mechanisms, including: ①Inhibition of tumors by inhibiting cell cycle regulatory kinase Aurora B Cell cycle progression; ② inhibit tumor angiogenesis by inhibiting VEGFR and PDGFR related to angiogenesis; ③ inhibit tumor local immunosuppressive cell growth by inhibiting CSF1R related to immune cell proliferation and activation.
On April 16, Microchip released an announcement stating that a randomized, double-blind, controlled, multi-center phase 3 clinical trial of Cioroni combined with paclitaxel weekly therapy for platinum-refractory or platinum-resistant relapsed ovarian cancer (CHIPRO ) Has also been approved in China.
